Please wait while the formulary information is being retrieved.
AVASTIN (BEVACIZUMAB)
- Metastatic colorectal cancer
- Metastatic renal cell carcinoma
- Nonsquamous non-small cell lung cancer
- Carcinoma of cervix
- Glioblastoma multiforme
- Malignant epithelial tumor of ovary
- Malignant neoplasm of fallopian tube
- Primary malignant neoplasm of peritoneum
25 mg/mL intravenous solution
- Dosage information is not available
Carcinoma of cervix
- Infuse 15 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
Glioblastoma multiforme
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
Malignant epithelial tumor of ovary
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
Malignant neoplasm of fallopian tube
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
Metastatic colorectal cancer
- Infuse 5 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 5 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 5 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 7.5 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 7.5 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 7.5 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 5 mg/kg over 10 minute(s) by intravenous route every 2 weeks at a rate of 0.5 mg/kg
- Infuse 5 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
- Infuse 7.5 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
Metastatic renal cell carcinoma
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
Nonsquamous non-small cell lung cancer
- Infuse 15 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
Primary malignant neoplasm of peritoneum
- Infuse 10 mg/kg over 90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 90 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- Infuse 10 mg/kg over 30 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 3 weeks
- Infuse 15 mg/kg over 30 minute(s) by intravenous route every 3 weeks
- Infuse 10 mg/kg over 30-90 minute(s) by intravenous route every 2 weeks
- Infuse 15 mg/kg over 30-90 minute(s) by intravenous route every 3 weeks
- natalizumab
- Tysabri
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- sunitinib
- Sutent
- Versacloz
Severe
Moderate
- erlotinib
- Tarceva
- Abnormal vaginal bleeding
- Alveolar hemorrhage
- Gastrointestinal fistula
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Intracerebral hemorrhage
- Lactating mother
- Necrotizing fasciitis
- Nephrotic syndrome
- New fistula formation involving an internal organ
- Posterior reversible encephalopathy syndrome
- Tracheoesophageal fistula
Contraindicated
- Acute myocardial infarction
- Angina
- Chemotherapy-induced neutropenia
- Chronic heart failure
- Erosive esophagitis
- Female hypogonadism
- Hypertension
- Impaired wound healing
- Invasive surgical procedure
- Neutropenic disorder
- Pregnancy
- Proteinuria
- Surgical wound dehiscence
- Thromboembolic disorder
- Transient cerebral ischemia
Severe
Moderate
- Secondary ovarian failure
AVASTIN (BEVACIZUMAB)
- Metastatic colorectal cancer
- Metastatic renal cell carcinoma
- Nonsquamous non-small cell lung cancer
- Carcinoma of cervix
- Glioblastoma multiforme
- Malignant epithelial tumor of ovary
- Malignant neoplasm of fallopian tube
- Primary malignant neoplasm of peritoneum
- Dyspnea
- Exfoliative dermatitis
- Gastrointestinal hemorrhage
- Hypertension
- Leukopenia
- Neutropenic disorder
- Proteinuria
- Rectal bleeding
- Secondary ovarian failure
- Stomatitis
- Venous thrombosis
- Abdominal pain with cramps
- Anorexia
- Arthralgias
- Back pain
- Diarrhea
- Dizziness
- Dry skin
- Dysgeusia
- Epistaxis
- Eye tearing
- Fatigue
- General weakness
- Headache disorder
- Myalgias
- Nausea
- Peripheral sensory neuropathy
- Rhinitis
- Upper respiratory infection
- Vomiting
More Frequent
Severe
Less Severe
- Chest pain
- Colitis
- Deep venous thrombosis
- Dehydration
- Hypersensitivity drug reaction
- Hyponatremia
- Hypotension
- Ileus
- Infection
- Kidney disease with reduction in GFR
- Skin ulcer
- Syncope
- Thrombocytopenic disorder
- Thrombotic disorder
- Alopecia
- Angina
- Constipation
- Dysarthria
- Dyspepsia
- Lymphopenia
- Muscle weakness
- Pain
- Pelvic pain
- Rectal pain
- Voice change
- Weight loss
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal vaginal bleeding
- Acute arterial thromboembolism
- Acute myocardial infarction
- Anaphylaxis
- Arterial aneurysm
- Aseptic necrosis of jaw bone
- Bloody vomit
- Cerebral ischemia
- Cerebrovascular accident
- Chronic heart failure
- Conjunctival hemorrhage
- Endophthalmitis
- Gastrointestinal fistula
- Gastrointestinal perforation
- Hemoptysis
- Hemorrhage
- Hypertensive crisis
- Hypokalemia
- Impaired wound healing
- Intestinal ischemic necrosis
- Intracerebral hemorrhage
- Nasal septal perforation
- Necrotizing fasciitis
- Nephrotic syndrome
- New fistula formation involving an internal organ
- Pancytopenia
- Perforation of gallbladder
- Polyserositis
- Posterior reversible encephalopathy syndrome
- Pulmonary hemorrhage
- Pulmonary hypertension
- Retinal detachment
- Surgical wound dehiscence
- Thrombotic thrombocytopenic purpura
- Tracheoesophageal fistula
- Transient cerebral ischemia
Less Severe
- Blurred vision
- Ocular inflammation
- Vitreous floater
- Wheezing
Contraindicated
None
Severe Precaution
Bevacizumab
Non-mandibular osteonecrosis reported. No antitumor activity observed in relapsed glioblastoma study. No safety and efficacy established.
- 1 Day – 18 Years
- Non-mandibular osteonecrosis reported. No antitumor activity observed in relapsed glioblastoma study. No safety and efficacy established.
Management or Monitoring Precaution
None
Bevacizumab
- Severity Level:
D
- Additional Notes: Insuf human data, animal data sug dev tox;weigh treatment benefit vs fetal risk
Contraindicated
Bevacizumab
Insuff human data; potentially harmful to infant based on mechanism of action
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data; potentially harmful to infant based on mechanism of action |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Bevacizumab
General-Increased risk for severe side effects, including sepsis, deep thrombophlebitis, arterial thromboembolism, hypertension, hypotension, edema, MI, GI hemorrhage.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | Y | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication can rarely cause a tear in the stomach/intestines (gastrointestinal perforation). It may also increase the risk of serious (possibly fatal) bleeding, such as bleeding from the stomach/intestines or in the brain. You should not receive this medication if you have any serious bleeding problems.<br /><br />Get medical help right away if you have any signs of these serious side effects, including bloody or black/tarry stools, persistent or severe stomach/abdominal pain, constipation with vomiting, vomit that is bloody or looks like coffee grounds, coughing up blood, shortness of breath, dizziness/fainting, unusual or persistent tiredness/weakness, severe headache, fever. This medication may also cause wounds to heal slowly or poorly or cause the wounds to break open. It can also rarely cause very serious (possibly fatal) skin and tissue infections that spread quickly.<br /><br />Get medical help right away if you have wounds that are not healing well, a fever, severe pain/redness/heat/swelling at the surgery site or other areas on the skin, fluid-filled blisters in the skin, discolored/scaling/peeling skin, confusion, dizziness, or fainting. You should not receive this medication for at least 4 weeks before and after a major surgery and until the wound from the surgery is fully healed.
| Carcinoma of cervix | |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| Glioblastoma multiforme | |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| Malignant epithelial tumor of ovary | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Malignant neoplasm of fallopian tube | |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| Metastatic colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| Metastatic renal cell carcinoma | |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| Nonsquamous non-small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| Primary malignant neoplasm of peritoneum | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| 0-9 | A-Z |
|---|---|
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| C39.9 | Malignant neoplasm of lower respiratory tract, part unspecified |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C53 | Malignant neoplasm of cervix uteri |
| C53.0 | Malignant neoplasm of endocervix |
| C53.1 | Malignant neoplasm of exocervix |
| C53.8 | Malignant neoplasm of overlapping sites of cervix uteri |
| C53.9 | Malignant neoplasm of cervix uteri, unspecified |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
Formulary Reference Tool